Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

Ovarian cancer isn't silent - learn the early warning signs. Persistent bloating, pelvic pain, urinary symptoms revealed.

For decades, gynecologic cancer treatment has used aggressive surgical intervention and chemotherapy. These methods often ...

Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

The legal issues raised by Trump sending the National Guard to L.A. Mystery of America's 'Lost Colony' may finally be solved ...

The addition of relacorilant to nab-paclitaxel significantly extended survival for women with platinum-resistant ovarian ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.